Australian Government
Repatriation Medical Authority

Amendment Statement of Principles concerning ISCHAEMIC HEART DISEASE (Reasonable Hypothesis) (No. 97 of 2021)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 20 August 2021

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

Professor Terence Campbell AM
Chairperson

Contents

1 Name

This is the Amendment Statement of Principles concerning *ischaemic heart disease (Reasonable Hypothesis)* (No. 97 of 2021).

2 Commencement

This instrument commences on 20 September 2021.

3 Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

4 Amendment

The Statement of Principles concerning *ischaemic heart disease (Reasonable Hypothesis)* (No. 1 of 2016) (Federal Register of Legislation No. F2016L00001) is amended in the following manner:

Section	Amendment
9(41)	*Replace the existing factor in subsection 9(41) with the following*: having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of ischaemic heart disease; Note: ***specified list of autoimmune diseases*** is defined in the Schedule 1 - Dictionary.
9(84)	*Replace the existing factor in subsection 9(84) with the following*: having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical worsening of ischaemic heart disease; Note: ***specified list of autoimmune diseases*** is defined in the Schedule 1 - Dictionary.
Schedule 1 – Dictionary	*Delete the existing definition of "specified autoimmune collagen vascular disease".*
Schedule 1 – Dictionary	*Insert the following definition of "specified list of autoimmune diseases" in alphabetical order*: ***specified list of autoimmune diseases*** means: (a) ankylosing spondylitis; (b) Behcet disease; (c) dermatomyositis; (d) eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); (e) giant cell (temporal) arteritis;

	(f) IgA vasculitis (Henoch-Schönlein purpura); (g) microscopic polyangiitis; (h) mucocutaneous lymph node syndrome (Kawasaki disease); (i) non-specific autoimmune vasculitis; (j) polyarteritis nodosa; (k) polymyositis; (l) psoriasis; (m) psoriatic arthritis; (n) rheumatoid arthritis; (o) Sjögren syndrome; (p) systemic lupus erythematosus; (q) systemic sclerosis; (r) Takayasu arteritis; (s) thromboangiitis obliterans (Buerger disease); or (t) granulomatosis with polyangiitis (Wegener granulomatosis).